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Abstract 
Background: There are limited data on admission trends and outcomes of individuals with 
bronchiectasis admitted to intensive care (ICU). Using national critical care data, we analysed 
admissions to ICU and estimated outcomes in terms of mortality in individuals with bronchiectasis and 
chronic obstructive pulmonary disease (COPD) admitted to ICU. 
Methods: Using data from the Intensive Care National Audit and Research Centre, admissions from 
bronchiectasis and COPD from 1/1/2009 to 31/12/2013 were extracted. Crude admission rates for 
bronchiectasis and COPD were calculated and Poisson regression was used to estimate unadjusted 
annual admission rate ratios. We investigated changes to length of stay on ICU, ICU mortality and in 
hospital mortality during the study period. We also analysed mortality rates in people with 
bronchiectasis and COPD aged 70 or above. 
Results: We found an annual increase of 8% (95% Confidence Interval [CI] 2 to 15%) in the number of 
ICU admissions from bronchiectasis, whilst the yearly increase in ICU admissions from COPD was 1% 
(95% CI: 0.3% to 2%). ICU and in-hospital mortality  in individuals with bronchiectasis remained high 
throughout the study , especially in people aged 70 years or above, whilst in people with COPD both 
ICU and in-hospital mortality decreased. 
Conclusion: Admission to ICU in people with bronchiectasis are uncommon, but are increasing in 
frequency over time, and carries a substantial mortality rate. This needs to be considered allocating 
health care resources and planning respiratory services. 
 
 
(236 words) 
 
Introduction 
Bronchiectasis is a chronic lung disease characterised by repeated episodes of infection and chronic 
inflammation.(1) Recent studies suggest that incidence(2), hospital admissions(3) and mortality(4) 
from bronchiectasis in the UK are increasing, but there are no data on admission rates to intensive 
care (ICU). There are also limited data on outcomes of individuals with bronchiectasis admitted to ICU 
in terms of survival. These data are important to help health care planning and form guidance for 
thresholds for admission to critical care. 
The aim of our study was to investigate trends in bronchiectasis admissions to ICU in the UK and 
estimate outcomes in patients with bronchiectasis admitted to ICU. To benchmark these data we also 
investigated these outcomes in patients with Chronic Obstructive Pulmonary Disease (COPD), a 
common chronic respiratory disease in the UK. In addition, we estimated financial impact of 
bronchiectasis admissions to ICU on secondary care services.  
Methods 
Data source 
We used data from the Intensive Care National Audit and Research Centre (ICNARC), an electronic 
database of patient outcomes from adult general critical care units across England, Wales and 
Northern Ireland.(5) 99% of adult critical care units contribute data to ICNARC, which includes 
information from 1.5 million individuals. Data from ICU admissions from adults over the age of 18 with 
bronchiectasis and COPD from 1st January 2009 to 31st December 2013 were extracted. 
Definition of outcomes 
Our definition of bronchiectasis admissions to ICU included patients whose main reason for admission 
to ICU was exacerbation of bronchiectasis and excluded individuals with cystic fibrosis. COPD 
admissions were defined as admissions whose main reason for admission was either COPD with acute 
lower respiratory infection; or COPD with acute exacerbation, cause unspecified. Patients who had 
COPD-bronchiectasis overlap(6) were excluded from these analyses (n=36). The ICNARC Coding 
Method is a hierarchical method specifically designed for coding reasons for admission to critical care. 
Primary reason for admission is mandated; however, secondary reason for admission is optional, 
unless the patient was admitted following surgery. There are currently no national criteria for 
admission to critical care for either bronchiectasis or COPD, and admissions are based on clinical 
discretion.  
ICU mortality was defined as the status at discharge from the ICU, whilst in-hospital mortality was 
defined as the status on discharge from hospital. We also extracted demographic information, 
intubation rates, length of stay on ICU (duration from date of admission to date of discharge from ICU 
or date of death), total hospital length of stay (date of admission to date of discharge from hospital or 
date of death), as well as mean Acute Physiology and Chronic Health Evaluation II (APACHE II) scores. 
Statistical Analysis 
Only summary data grouped by calendar year were available for these analyses. We calculated crude 
admission rates for bronchiectasis and COPD for each year by dividing the number of admissions from 
bronchiectasis or COPD by the total number of admissions to ICU. Poisson regression modelling(7) was 
used to estimate crude annual admission rate ratios. We calculated the cost of critical admissions from 
bronchiectasis for each year by multiplying the cost of a critical care bed day in the NHS with single 
organ support for the 2012-2013 financial year (www.dh.gov.uk) by the median length of stay on ICU 
and number of admissions for each calendar year. We developed an unadjusted Poisson regression 
model to predict future critical care admissions from bronchiectasis for the year 2020 and estimated 
cost of critical care admissions for that year without adjusting for inflation costs or changes to market 
forces. We investigated changes in mean age at admission, mean APACHE II scores, rates of intubation, 
ICU and in-hospital mortality over the study period in people with bronchiectasis and COPD.  As 
increasing age is strongly associated with poor survival in bronchiectasis,(8) and COPD(9) we assessed 
these outcomes in older individuals  with COPD and bronchiectasis. We pragmatically chose 
individuals aged 70 years or above in these separate analyses Two-sided likelihood ratio, unpaired t 
tests, Chi squared and Wilcoxon rank sum tests were used for hypothesis testing. Stata v12 (College 
Station, Texas) was used for all statistical analyses. 
Results 
There were 614,352 admissions to ICU across 219 critical care units between 2009 and 2013, of which 
536 (0.1%) were due to bronchiectasis and 19,754 (3.2%) due to COPD. Admissions from 
bronchiectasis increased from 74 in 2009 to 121 in 2013, equating to a crude annual increase of 8% 
(Rate Ratio [RR] 1.08; 95% Confidence Interval [CI]: 1.02 to 1.15; p=0.01). Individuals with 
bronchiectasis were more frequently female (57.5%) and the mean age at admission increased from 
56.6 (standard deviation [SD] 18) to 65.8 years (SD 15.2) during the study period (linear regression 
p=0.042). However, rates of intubation (47.9% vs 44.6%; p=0.65) and mean APACHE II acute physiology 
scores remained similar (12.7 vs. 13.5; p=0.17) during this time. ICU mortality did not change (27.0% 
vs. 28.9%; p=0.83), neither did in hospital mortality (35.7% vs. 33.9%; p=0.86) (see Table 1).  There 
was also no change in median length of stay in ICU (p=0.21) or median length of stay in hospital 
(p=0.36) (see Table 2). During the five year study period, the estimated financial burden on the 
National Health Service (NHS) in terms of critical care bed days from bronchiectasis increased 
marginally from £189,144 to £298,967 per year (see Table 2). Using an unadjusted Poisson regression 
model, we estimate that by 2020, there will be close to 220 critical care admissions per year from 
bronchiectasis, which will cost the health service almost £500,000 annually in critical care bed day 
costs.  
In contrast, there were 3126 admissions due to COPD in 2009, which rose to 4652 in 2013.  The 
unadjusted year on year increase in COPD admissions was 1% (RR 1.010, 95% CI: 1.003-1.023; 
p=0.012). The mean age at admission remained static (67.5 years [SD 10.6] in 2009 vs. 67.9 years [SD 
10.6] in 2013; p=0.16), but ICU mortality decreased during the study period (20.5% vs. 18.0%; p=0.02), 
as did in-hospital mortality (30.7% vs. 26.7%; p=0.005) (see Table 1). The proportion of individuals with 
COPD who were intubated also decreased during this time (53.7% vs. 44.2%; p<0.001).  
In separate analyses of 219 people with bronchiectasis aged 70 or above, we found that ICU mortality 
was higher compared to that amongst those aged under 70 (31.1% vs. 18.3%; p<0.001) despite having 
similar mean APACHE II acute physiology scores. Furthermore, in hospital mortality in individuals with 
bronchiectasis aged 70 or above was almost double compared to individuals with bronchiectasis under 
70 (47.4% vs. 24.6%; p<0.001). During the study period, patients with bronchiectasis aged 70 or above 
had substantially higher rates of death whilst on ICU (23.1% vs. 31.1%; p=0.03) and during hospital 
admission (36.4% vs. 46.6%; p=0.04) than individuals with COPD of the same age group (see Table 3). 
Individuals with bronchiectasis over the age of 70 were also less likely to be intubated compared to 
those less than 70 years. However, the proportions of individuals over the age of 70 with 
bronchiectasis and COPD who were intubated were similar (41.6% vs. 42.2%; p=0.90) (see Table 3). 
 
 
 
 
 
 
 
Table 1: Crude admission rates, Poisson regression modeling of admissions, mortality and median ICU 
length of stay in people with Bronchiectasis and Chronic Obstructive Pulmonary Disease (COPD) 
 
 
 
 
 
Bronchiectasis 
Number of 
admissions 
Person 
years  
Crude 
admission rate 
per 100,000 
person years 
(95% CI) 
Crude 
admissions 
rate ratio 
(95% CI) 
Number of 
ICU deaths 
(%) 
Number of 
hospital 
deaths (%) 
Year       
2009 74 97,457 75.9  
(60.5-95.4) 
1.00 20 (27.0) 25 (35.7) 
2010 78 114,207 68.3  
(54.7-85.3) 
0.90  
(0.65-1.24) 
18 (23.1) 31 (41.3) 
2011 108 128,659 83.9  
(69.5-101.4) 
1.11  
(0.82-1.49) 
22 (20.4) 32 (31.4) 
2012 155 137,062 113.1 
(96.6-132.7) 
1.49 
(1.13-1.96) 
31 (20.00 48 (31.8) 
2013 
 
121 136,877 88.4  
(74.0-105.6) 
1.16  
(0.87-1.55) 
*p for 
trend=0.022 
35 (28.9) 40 (33.9) 
COPD       
Year       
2009 3126 97,457 3204.6  
(3094.2-3318.9) 
1.00 642 (20.5) 941 (30.7) 
2010 3675 114,207 3217.8  
(3115.5-3223.6) 
1.01  
(0.96-1.05) 
717 (19.5) 1096 
(30.4) 
2011 3924 128,659 3049.9  
(2956.0-3146.9) 
0.95  
(0.91-1.00) 
718 (18.3) 1109 
(28.8) 
2012 4377 137,062 3193.4  
(3100.2-3289.5) 
0.99  
(0.95-1.04) 
818 (18.7) 1184 
(27.4) 
2013 
 
4652 136,877 3398.7  
(3302.4-3497.8) 
1.06  
(1.01-1.11) 
*p for 
trend=0.0003 
837 (18.0) 1220 
(26.7) 
*p value for likelihood ratio test         
 
 
 
 
Table 2: Median length of stay on intensive care, median length of stay in hospital and associated costs 
for individuals with bronchiectasis 
Bronchiectasis Median length of stay 
on ICU (IQR)# 
Median length of stay 
in hospital (IQR)# 
Cost on NHS in terms of 
critical care admission (£) 
Year    
2009 3.0 (1.0-5.0) 14 (7-24) 189,144 
2010 3.5 (1.4-6.4) 14 (7-29) 232,596 
2011 2.1 (1.0-5.1) 17 (7-33) 193,233 
2012 3.8 (1.1-7.3) 16 (8-30) 501,828 
2013 
 
2.9 (1.4-7.3) 12 (6-25) 298,967 
#length of stay in days 
Table 3: Characteristics of individuals with bronchiectasis and COPD aged 70 or above admitted to 
intensive care 
 Individuals with 
bronchiectasis aged ≥70 years 
(n=219) 
Individuals with COPD aged 
≥70 years (n=8,844) 
Mean age at admission (SD) 76.6 (5.0) 76.9 (5.1) 
Male (%)  98 (44.7) 4567 (51.6) 
Mean APACHE II acute physiology 
score (SD) 
13.3 (5.9) 12.5 (5.6) 
Number of people intubated (%) 91 (41.6) 3727 (42.2) 
Number of ICU deaths (%) 68 (31.1) 2042 (23.1) 
Number of hospital deaths (%) 102 (46.6) 3215 (36.4) 
Median length of stay on ICU (IQR) 2.9 (1.1-6.4) 2.8 (1,2-5.9) 
 
Discussion 
To our knowledge, this is the first study to use national data to determine trends in ICU admissions 
amongst individuals with bronchiectasis. We found that the number of patients with bronchiectasis 
admitted to ICU is increasing. The mean age at admission increased during our study period but there 
was no change to length of stay on ICU. Throughout the five year study period, ICU and in-hospital 
mortality in people with bronchiectasis remained substantially high, whilst both decreased in people 
with COPD. We also found that both ICU and in-hospital mortality was highest in individuals with 
bronchiectasis aged 70 and above. 
On the basis of our findings, we estimate the annual financial burden from bronchiectasis critical care 
admissions alone in the UK will be almost £500,000 by 2020, although this likely to be an 
underestimation, as it assumes only single organ support and does not take into account inflation 
costs and changes to market forces. 
We used a large, comprehensive dataset that includes admissions across almost all adult critical care 
centres in England, Wales and Northern Ireland, including specialist tertiary centres and district 
general hospitals. The ICNARC dataset has been shown to be broadly representative of the UK 
population of patients admitted to ICU.(10) This has enabled us to estimate a realistic disease burden 
in terms of critical care admissions without sampling bias. The long study period has also enabled us 
to examine changes to age at admission, rates of intubation, ICU mortality, in-hospital mortality and 
length of stay. 
One of the limitations of our study is that only summary data were available, hence we were unable 
to standardise our admission rates to account for the increase in the number of critical care units 
contributing to ICNARC. Hence, it is possible that the increase in admissions seen in our study is due, 
at least in part, to increased diagnosis of cases of bronchiectasis in the UK. Another potential limitation 
relates to the validity of and accuracy of diagnostic coding of ICU admission data. We have not 
validated diagnoses of bronchiectasis or COPD within this dataset, but a previous study has shown 
that  validity of admission coding within ICNARC is high.(11) Furthermore, the demographic features 
of individuals with bronchiectasis in these data are consistent with the UK population of patients with 
bronchiectasis.(12, 13) However, given that the diagnosis of COPD is co-existent in 36% of individuals 
with bronchiectasis,(14) there is likely to be some diagnostic imprecision within our dataset, including 
undiagnosed Bronchiectasis-COPD overlap syndrome (BCOS)(6) that may be included in the COPD 
population.  Nevertheless, our study demonstrates a high ICU and in-hospital mortality rate in people 
with identified bronchiectasis, especially in those aged 70 years or above. Although this may be partly 
explained by other factors that influence mortality, this does not detract from our finding that survival 
in these individuals is poor. We were been unable to identify patients who have had more than one 
admission to critical care. However, we believe that repeated admissions to critical care would not be 
the main reason for the rising trends seen, given the substantially high mortality rate throughout the 
study. 
There are sparse data on ICU admission rates in people with bronchiectasis, as well as outcomes with 
regards to mortality. A French study of 48 patients with bronchiectasis admitted to an intensive care 
unit over a 10 year period suggested that age over 65 years and long term oxygen therapy use were 
risk factors for increased mortality on ICU.(15) A single centre study from 1996 to 2004 by Alzeer et 
al. reported that the mean age of patients with bronchiectasis admitted to ICU was 63.5 years.(16) 
This study also found that older patients with bronchiectasis admitted to ICU had a worse outcome in 
terms of survival.(16) Both studies report variable ICU mortality rates, ranging from 19 to 34%,(15, 16) 
and long term oxygen therapy was also associated with increased mortality.(16)  
In summary, this is the first ever national study of ICU outcomes in patients with bronchiectasis. These 
data derived from the UK have identified the increasing demand on critical care services and the 
financial impact of this on secondary care services. We have also highlighted the poor prognosis of 
individuals with bronchiectasis admitted to ICU, especially in the older population of 70 years or older. 
These data will aid updates in UK national bronchiectasis guidelines (17) and may help guide clinicians 
in the thresholds for admission to critical care. 
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